Newron Pharmaceuticals S.p.A.
NWRN | SW
Overview
Corporate Details
- ISIN(s):
- IT0004147952
- LEI:
- 8156002F8C11F80A9740
- Country:
- Italy
- Address:
- VIA MEUCCI, 3, 20091 BRESSO
- Website:
- https://www.newron.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Newron Pharmaceuticals S.p.A. is a clinical-stage company focused on the discovery and development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS). Founded in 1999, the company's scientific work centers on creating new therapeutic classes to address significant unmet needs in difficult-to-treat indications such as Parkinson’s disease and schizophrenia. Newron leverages its experienced team of scientists and clinicians to advance drug candidates from discovery through to commercialization, often through strategic partnerships with other specialized pharmaceutical companies to bring treatments to patients globally.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Newron Pharmaceuticals S.p.A..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-12 07:00 |
Regulatory News Service
Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide…
|
English | 17.2 KB | |
| 2025-08-12 02:00 |
Regulatory News Service
EQS-News: Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with…
|
English | 15.8 KB | |
| 2025-08-12 02:00 |
Regulatory News Service
EQS-News: Newron beginnt Rekrutierung für zulassungsrelevantes Phase-III-Entwic…
|
German | 18.5 KB | |
| 2025-08-11 07:00 |
Environmental & Social Information
Newron notes the publication of new preclinical research suggesting evenamide a…
|
English | 19.4 KB | |
| 2025-08-11 02:00 |
Regulatory News Service
EQS-News: Newron notes the publication of new preclinical research suggesting e…
|
English | 17.8 KB | |
| 2025-08-11 02:00 |
Regulatory News Service
EQS-News: Newron verweist auf die Veröffentlichung neuer präklinischer Forschun…
|
German | 20.9 KB | |
| 2025-05-12 07:00 |
Regulatory News Service
Newron gibt Genehmigung fur zulassungsrelevantes Phase-III-Entwicklungsprogram…
|
German | 12.6 KB | |
| 2025-05-12 02:00 |
Regulatory News Service
EQS-Adhoc: Newron gibt Genehmigung für zulassungsrelevantes Phase-III-Entwickl…
|
German | 11.3 KB | |
| 2025-05-12 02:00 |
Legal Proceedings Report
EQS-News: Newron announces approval for pivotal Phase III ENIGMA-TRS program w…
|
English | 19.4 KB | |
| 2025-05-12 02:00 |
Regulatory News Service
EQS-News: Newron gibt Genehmigung für zulassungsrelevantes Phase-III-Entwicklu…
|
German | 22.8 KB | |
| 2025-04-24 16:22 |
Director's Dealing
Newron Pharmaceuticals S.p.A.: Tuula Martin, buy
|
English | 6.3 KB | |
| 2025-04-23 11:30 |
Post-Annual General Meeting Information
Generalversammlung 2025 von Newron Pharmaceuticals: Chris Martin zum neuen Verw…
|
German | 7.5 KB | |
| 2025-04-07 17:17 |
Director's Dealing
Newron Pharmaceuticals S.p.A.: Stefan Weber, buy
|
English | 5.9 KB | |
| 2025-04-01 07:00 |
Earnings Release
Newron gibt Geschaftsergebnisse 2024 und Ausblick 2025 bekannt
|
German | 12.5 KB | |
| 2025-03-24 17:45 |
Board/Management Information
Newron schlagt renommierten Biopharma-Firmengrunder und -Unternehmer Dr. Chris …
|
German | 8.9 KB |
Automate Your Workflow. Get a real-time feed of all Newron Pharmaceuticals S.p.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Newron Pharmaceuticals S.p.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
